Essential fatty acids (EFA) have proved to be important for normal bone mineral density (BMD) and bone growth in animal studies. Patients with cystic fibrosis often have low serum EFA levels, and low BMD has also been reported in patients with normal anthropometry. The aim of the present study was to analyse if BMD during a 2-year period was related to fatty acid status in patients with cystic fibrosis. Fifty-four patients, aged 6 -33 years, were studied prospectively. BMD was measured with dual X-ray absorptiometry, and fatty acid concentrations in serum phospholipids were determined with capillary GLC. The cystic fibrosis patients showed low linoleic acid concentration and a high arachidonic acid (AA):DHA ratio in serum. The high eicosatrienoic acid:AA ratio, an indicator of EFA deficiency, increased further over 2 years, as did the total concentration of saturated fatty acids. In the adults there were no significant changes in fatty acids during the study. In the children, positive correlations were found between palmitic acid and bone mineral content in the lumbar spine and femoral neck. The lumbar spine BMD Z score correlated negatively with the AA:DHA ratio. No correlation was seen in adults except for a positive correlation between EFA deficiency index and the areas of lumbar spine and femoral neck. The present results imply that fatty-acid status influenced BMD in cystic fibrosis children, but not in adults, indicating that fatty-acid status would be important for bone growth.
Bone mineral density (BMD) has been reported to be low in patients with cystic fibrosis (CF), mainly related to malnutrition, pulmonary function and steroid treatment (Haworth et al. 1999; Conway et al. 2000; Gronowitz et al. 2003; Buntain et al. 2004) . Some authors report normal BMD in CF patients, compared with other patients with similar growth (Salamoni et al. 1996; Hardin et al. 2001; Sood et al. 2001) , suggesting that a common denominator for growth might be involved.
Essential fatty acids (EFA) are associated with normal growth (Holman, 1968) and in animals also with normal bone mass (Watkins et al. 2001c) . Arachidonic acid (AA; 20 : 4n-6) is the main long-chain PUFA synthesised from linoleic acid (LA; 18 : 2n-6), the EFA that has been claimed as the more important of the two EFA (Holman, 1968) . AA is the substrate for the synthesis of eicosanoids, an important group of mediators of metabolism and inflammation, for example, prostaglandin (PG) E 2 and leucotrienes. PGE 2 is a modulator of bone growth (Marks & Miller, 1993; Watkins et al. 2001c) , but leucotrienes also influence bone metabolism (Garcia et al. 1996) .
Increasing documentation is now available on the influence of the n-3 EFA series on bone metabolism (Watkins et al. 2001a) . There is a balance in the synthesis of longchain PUFA from the EFA, LA and a-linolenic acid (18 : 3n-3), which is determined by the competition of enzymes for elongation and desaturation of those fatty acids and the endogenous fatty acids of the n-7 and n-9 series. The influence of this integrated system, together with heredity, systemic hormones, cytokines, diet and other local factors constitute a complicated network controlling bone homeostasis (Marks & Miller, 1993; Gunnes & Lehmann, 1995; Garcia et al. 1996; Karsenty, 1999; Watkins et al. 2001a,c) .
Abnormal AA metabolism has been documented in different systems in CF patients (Carlstedt-Duke et al. 1986; Levistre et al. 1993; Berguerand et al. 1997; Miele et al. 1997) , and the metabolism of the precursor LA has also been found to be altered, resulting in low concentrations of LA in most analysed tissues (Underwood et al. 1972; Lai et al. 2000; Strandvik et al. 2001b ). An abnormal ratio between AA and the long-chain PUFA product of a-linolenic acid, DHA (22 : 6n-3), has been reported in pancreatic tissue of CF transmembrane conductance regulator -/ -mice and in serum of patients with CF (Freedman et al. 1999 (Freedman et al. , 2004 Strandvik et al. 2001a) .
We have previously reported low BMD in patients with CF despite normal growth and good lung function (Gronowitz et al. 2003 (Gronowitz et al. , 2004 . The aim of the present study was to investigate, during a 2-year prospective study (Gronowitz et al. 2004) , if the abnormal fatty acid metabolism in CF, as reflected in serum phospholipid fatty acids, was associated with low bone mass in the lumbar spine (LS) and femoral neck (FN) in children and adult patients.
Subjects and methods

Subjects
Fifty-four CF patients (twenty-five males and twenty-nine females), consisting of thirty-five children and nineteen adults regularly attending the West Swedish CF Centre (Gothenburg, Sweden), with a median age of 16·0 (range 6-33) years, were investigated. Patients were consecutively included in the study except for pregnant or transplanted patients and investigated in stable condition without acute infections. All patients had pathological sweat tests (Cl . 60 mmol/l) and typical clinical symptoms. Fifty patients had pancreatic insufficiency, ten patients had slight biochemical liver involvement and five patients had clinical liver disease. Four patients had CF-related diabetes mellitus. Thirty-three patients were homozygotes for dF508, and seventeen were compound heterozygotes for dF508. In two patients only one mutation was identified. A total of twelve mutations were identified in the patients and no patient had two unidentified mutations (Strandvik et al. 2001a) . The average height, weight (Table 1 ) and lung function were within the normal range and clinical and nutritional data and biochemical markers in relation to BMD during the 2-year study have been reported previously (Gronowitz et al. 2004) . Most children had a normal annual accretion of BMD. No dietary changes were performed during the study period. All patients were physically active as part of our treatment policy (Blomquist et al. 1986; Lannefors et al. 2004) .
Fatty acids in serum phospholipids
Serum samples were taken in the morning at the annual check up of the patients after an overnight fast in relation to investigation of BMD (Gronowitz et al. 2004) . The serum was frozen at 2 708C until analysis within 2 weeks. Total lipids from the serum were extracted, fractionated on a single SEP-PAK aminopropyl cartridge (Waters Corp., Milford, MA, USA), transmethylated and separated by capillary GLC in a HewlettPackard 6890 gas chromatograph as described previously (Korotkova et al. 2001) . The fatty acid 21: 0 was used as internal standard and the fatty acid methyl esters identified by comparison with retention times of pure reference substances (Sigma Aldrich Sweden AB, Stockholm, Sweden). The CV for interassays were 1·7 % for palmitic acid (16 : 0) and 0·8 % for LA and 1·5 % for AA (n 25). The ratio of eicosatrienoic acid (ETA; Mead acid; 20 : 3n-9):AA was used to define the deficiency state; a ratio of .0·025 was used as the biochemical criterion of EFA deficiency (Siguel et al. 1987) .
Reference values for the fatty acid pattern were obtained from 152 healthy individuals (100 subjects 6-18 years and fifty-four 18 -50 years).
Dual X-ray absorptiometry
Dual X-ray absorptiometry was performed with a Hologic QDR 2000 (Hologic Inc., Bedford, MA, USA) at baseline and after 2 years. The CV with spine phantom measurements in the Hologic 2000 during the period 1996 to 2000 was 0·48 %. Reference values were obtained from the manufacturer and expressed in age-and sex-matched Z scores. Reference values for FN for children aged 9-19 years of age were obtained from the literature (Bachrach et al. 1999) . Findings in a longitudinal community-based cohort of 234 healthy 16-year-old individuals in Gothenburg followed up annually until age 21 years concurred well with the manufacturer's values, the deviation being 0 -2 % in the females and 24 to 2 % in the males.
Statistical analysis
Statistical analysis was performed with Student's t test, one-sample t test and paired t test when data were normally distributed, otherwise with non-parametric tests such as the MannWhitney U test and Wilcoxon paired signed rank test. Univariant correlation was made with linear regression and with Spearman rank correlation. Mean values and SD were used, if not otherwise indicated. Z score was used both for BMD and anthropometric 
* Sixteen males and nineteen females aged less than 20 years. † Nine males and ten females aged more than 20 years. For details of subjects and procedures, see this page.
data as both children and adults were included in the study. Statistical significance was set at P, 0·05.
Results
The young patients grew normally during the 2 years, as evidenced by unchanged Z score for height and weight (Gronowitz et al. 2004 ). The adult patients had a lower Z score for height than the children (P, 0·05), but still not significantly different from normal; their status was stable ( Table 1) . The serum concentration of fatty acids in phospholipids differed significantly in most fatty acids compared with those in controls in both adults and children. In the children, LA and all long-chain PUFA were decreased except ETA and the ETA:AA ratio, which were increased, indicating EFA deficiency. The AA:DHA ratio was high (Table 2) . During the study period, oleic acid, LA and total MUFA concentration decreased in the CF children ( Table 2 ). The ETA concentration and the ETA:DHA ratio and total saturated fatty acids concentration increased significantly (Table 2 ). In the adult CF patients there were no changes during the study except for a marginal increase of total saturated fatty acids concentration.
There was no correlation between the change in weight or height and serum concentration of EFA.
The mean BMD Z score in children and adults was slightly lower in the LS (20·7 and 2 0·5, respectively) and in the FN (2 0·4 and 21·2, respectively) and did not change over the 2 years (Gronowitz et al. 2004 ). The bone growth was significant in the children and, as expected, no change was seen in the adults (Table 3) .
Data of bone growth showed similar correlation with phospholipid fatty acids at baseline and follow-up. Changes in bone growth were reported when relevant, but otherwise only associations at 2-year follow-up are given. ETA, eicosatrienoic acid; AA, arachidonic acid; SFA, saturated fatty acids. Mean value was significantly different from that of the reference group (controls): * P#0·05, ** P#0·01, *** P# 0·001. The change over the 2 years was significant: † P# 0·05, † † P#0·01, † † † P#0·001. ‡ Reference (control) values are for 100 children aged less than 18 years and for fifty-two adults aged more than 18 years. blood sedimentation rate serum For details of subjects and procedures, see p. 1160.
Total correlation of saturated fatty acids was only correlated with FN parameters, but the association disappeared when the children and adults were analysed separately. Palmitic acid (16 : 0) was only associated with bone growth in children; the relationship to LS is presented in Fig. 1 and the correlation with FN bone mineral content and FN area were 0·54 (P¼0·001) and 0·40 (P¼0·02), respectively.
The LS Z score and the change in LS Z score showed an inverse correlation in the CF children with AA:DHA ratio (Fig. 2) . This was supported by the significant correlation between the change of LS BMD Z score and the phospholipid concentration of DHA (r 0·40; P¼0·03).
No correlations were found with AA, LA or a-linolenic acid concentrations. The EFA deficiency ratio ETA:AA showed strong correlations with the LS (P, 0·01) and FN (P,0·001) areas in both children and adults.
Discussion
To the best of our knowledge, the present study is the first to show an association in human subjects between EFA and BMD and the first one to indicate an association between lipids and bone growth in children with CF.
The serum phospholipid EFA pattern differed as expected in the CF patients compared with controls (Rogiers et al. 1980 , Strandvik et al. 2001b in both children and adults. The anthropometric data were within the normal range, although the adult patients had a lower Z score for height compared with children. This might be due to the fact that they had not had centralised treatment from early childhood, since the West Swedish CF Centre was not established in Gothenburg before 1992. An association between BMD and saturated fatty acids in serum has previously been documented in healthy children (Gunnes & Lehmann, 1995) . We also found a similar correlation in the children but not in adults with CF. This correlation was mainly referred to palmitic acid (Fig. 1) , a correlation probably reflecting the children's good nutritional status since palmitic acid is endogenously synthesised or obtained by diet. A strong negative correlation between BMD and bone accretion and AA:DHA ratio was found at 2-year follow-up, and this was associated with DHA concentration and not with AA, indicating 
BMD, bone mineral density; BMC, bone mineral content. Mean value was significantly different to that of the adult group: ** P# 0.01, *** P#0·001. † Mean value was significantly different to that at baseline (P#0·001). For details of subjects and procedures, see p. 1160. and bone parameters at 2-year follow-up in thirty-four children ( † ) and nineteen adults ( ) with cystic fibrosis. (A) Relationship between palmitic acid and the Z score of bone mineral density of the lumbar spine (LS) (total patients r 0·3 (P, 0·04), children r 0·4 (P, 0·02), adults r 0·1 (NS)). (B) Relationship between palmitic acid and bone mineral content (BMC) of the LS (total patients r 0·5 (P, 0·0001), children r 0·6 (P, 0·0001), adults r 0·2 (NS)). (C) Relationship between palmitic acid and area of the LS (total patients r 0·5 (P, 0·0002), children r 0·6 (P, 0·0005), adults r 0·3 (NS)). The medians and 95 % CI are indicated.
that the balance between n-6 and n-3 fatty acids is of importance. This corroborates previous studies in animals (Watkins et al. 2001b) . EFA, by modulating eicosanoids, leptin and IGF-1, are involved in the regulation of bone growth and bone status (Watkins et al. 2001b,c) . IGF-1 is related to lean body mass and has been reported to be decreased in CF patients (Arumugam et al. 1998; Sermet-Gaudelus et al. 2003) . Lean body mass was normal in our patients (Gronowitz et al. 2003) , as were serum leptin levels (A Lindblad, personal communication). Leptin has previously been shown to be decreased in CF patients related to the decreased fat mass (Arumugam et al. 1998) . On the other hand, leptin has also been reported to be increased despite low fat mass, probably related to the impact of cytokines in response to infection and inflammation (Ahme et al. 2004) . A weakness in the present study is that we did not have the opportunity to analyse these hormones, but the normal anthropometry, good lung function, normal lean body mass and relatively normal bone mass suggest that the hormones probably would not be significantly affected in our group of patients. Nor did we find any correlations between EFA and clinical infection parameters such as blood sedimentation rate serum and IgG.
The serum concentration of LA was decreased in our patients as has generally been reported in CF patients (Kuo et al. 1962; Strandvik et al. 2001a) , more marked during early infancy and during adolescence (Lai et al. 2000) . In the rat we have recently shown that EFA deficiency during the perinatal period can programme for low trabecular BMD in the adult animal (Korotkova et al. 2005) . It might be speculated that severe EFA deficiency in the perinatal period (Lai et al. 2000) could contribute to the low BMD often reported in CF. Such a hypothesis is partly supported by our previous finding of normal bone accretion during childhood, indicating that the low BMD must start early, either related directly to the CF transmembrane conductance regulator or to early environmental influences (Gronowitz et al. 2004) .
The importance of EFA for bone metabolism has been well documented (Marks & Miller, 1993; Watkins et al. 2001a,b,c) . PGE 2 , one important product of AA, affects bone metabolism. In CF, AA release is increased (Carlstedt-Duke et al. 1986) and since this step is rate limiting for PG synthesis, that will explain the high levels of prostanoids in CF (Strandvik et al. 1996) . Both bone formation and bone resorption are influenced by PGE 2 and its effect on bone is dose dependent. Low levels of PGE 2 enhance bone formation by osteoblasts, while, at higher concentrations, PGE 2 suppresses osteoblast differentiation and promotes bone resorption by osteoclasts (Marks & Miller, 1993; Watkins et al. 2001c ). Moreover, leucotriene B 4 , another product of AA, which stimulates osteoclastic bone resorption in vivo and in vitro (Watkins et al. 2001c) , has been shown to be increased in CF (Shimizu et al. 1994) . The low LA concentration in CF is supposed to be secondary to the abnormal AA release (Strandvik, 2004 ) and, if not compensated for, it will progress and thus the AA synthesis might decrease, which will eventually also decrease the eicosanoid synthesis. In the present study, the inverse relationship of BMD accretion to the AA:DHA ratio at 2 years might reflect an influence on eicosanoid metabolism favouring bone growth, i.e. that the decrease during the 2-year period of n-6 fatty acids and especially the decrease of AA might probably have decreased PGE 2 synthesis and decreased the n-6:n-3 ratio and consequently decreased bone resorption. Due to ethical reasons bone biopsies could not be performed and the specific EFA ratio in bone tissue could therefore not be analysed. Diet, including vitamin D and Ca intake, was not changed during the study (Gronowitz et al. 2004) . There was no indication of increased intake of n-3 fatty acids during the study period either.
The present findings imply that changes in serum EFA can be significant during a 2-year period in stable patients and also that the balance between n-6 and n-3 fatty acids might be important for long-term bone growth as recently confirmed in experimental studies (Korotkova et al. 2004 (Korotkova et al. , 2005 . The fatty-acid status seems to be especially important in growing children, but to evaluate the impact in adults, probably a larger study sample and longer observation period are needed. Furthermore, a slight EFA deficiency, as documented by the increasing ETA:AA ratio over 2 years, might not be detrimental for bone mass in CF, possibly due to modulations in PG metabolism. If this would be the case, PG metabolites in urine might be valuable indicators of bone metabolism in further studies. Prospective intervention studies must be performed in order to find which EFA levels would optimise bone growth in CF children. If our finding has relevance for healthy children, the ideal fat intake to obtain optimal peak bone mass would need special attention. DHA ratio and Z scores of bone mineral density of the LS at 2-year follow-up (total patients r 2 0·40 (P, 0·004), children r 2 0·39 (P, 0·0035), adults r 2 0·23 (NS)). (B) Relationship between AA : DHA ratio and change in Z scores of bone mineral density of the LS over the 2 years (total patients r 2 0·34 (P, 0·01), children r 2 0·38 (P, 0·02), adults r 2 0·24 (NS)). The medians and 95 % CI are indicated.
